Tags : Moderate-To-Severe Chronic Plaque Psoriasis

Almirall’s Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe

Vartika Singh September 19, 2018

Shots: Ilumetri’s (tildrakizumab) approval is based on the positive results from reSURFACE 1 and 2 P-III clinical trial, testing its safety and efficacy in >200 clinical sites worldwide reSURFACE 1 […]readmore

Tags : Moderate-To-Severe Chronic Plaque Psoriasis

Almirall’s Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Moderate-To-Severe Chronic Plaque Psoriasis

Almirall’s Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company